arfolitixorin + fluorouracil + oxaliplatin

**Arfolitixorin + fluorouracil + oxaliplatin** (commonly referred to as **ARFOX**) is a combination chemotherapy regimen under investigation for the treatment of metastatic colorectal cancer (mCRC). Arfolitixorin is an immediately active form of folate ([6R]-5,10-methylenetetrahydrofolate), intended to enhance the antitumor activity of fluorouracil (5-FU) by stabilizing the ternary complex formed with thymidylate synthase, thereby improving inhibition of DNA synthesis in cancer cells. Oxaliplatin is a platinum-based alkylating agent that inhibits DNA replication. The ARFOX regimen is being evaluated in clinical trials for efficacy and safety, particularly as a first-line treatment for mCRC. Studies suggest that arfolitixorin may overcome certain limitations of traditional folates like leucovorin, such as pharmacokinetic variability and dependence on metabolic activation[3][4][5][2][1].

Other names

arfolitixorin + 5-fluorouracil + oxaliplatinARFOX